Menu Close
Close
Refer A Friend
Get in Touch

Chronic Inflammatory Demyelinating Polyneuropathy Clinical Trials

Neurology

Living with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)?

Clinical Trials May Help Explore Potential Treatment Options

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare neurological disorder in which the immune system attacks the protective myelin covering of the peripheral nerves. As that covering is damaged, nerve signals slow down or stop getting through, which leads to progressive weakness, numbness, tingling, and loss of function, most often in the legs and arms.

CIDP can follow a steadily progressive course or a relapsing and remitting one. Many people find that their symptoms are controlled only as long as treatment continues, and that function declines again when treatment is reduced or delayed. Fatigue, difficulty walking, trouble with balance, and loss of hand strength are common parts of daily life with the condition.

If you are an adult living with a confirmed diagnosis of CIDP and you currently depend on treatment to manage it, Revival Research Institute is conducting CIDP Clinical Trials evaluating an investigational treatment approach for adults with this condition.

Are You Eligible to Participate?

To qualify for the Chronic Inflammatory Demyelinating Polyneuropathy Clinical Trials, participants must:
  • Be an adult male or female, 18 years of age or older
  • Have a documented diagnosis of CIDP confirmed by a physician
  • Currently be receiving and dependent on immunoglobulin therapy, corticosteroids, or another standard treatment for CIDP
  • Have ongoing difficulty with walking, arm function, or hand function due to CIDP
  • Have had stable symptoms and a stable treatment dose for the past 12 weeks

*Additional criteria may apply.

Participation is free of cost. To learn more or determine whether you may qualify, complete the form below. A member of our research team will contact you to discuss potential eligibility.

This field is for validation purposes and should be left unchanged.
Who is this information for?*(Required)

Please provide YOUR contact information only.

Name(Required)
Best Time to Call(Required)
User Agreement(Required)
This is our Privacy Policy.

Chronic Inflammatory Demyelinating Polyneuropathy Clinical Trials Flyer

About Chronic Inflammatory Demyelinating Polyneuropathy Clinical Trials

Managing CIDP usually means ongoing treatment, regular monitoring, and periodic adjustment as symptoms change. Because response varies from person to person, and treatment often has to continue indefinitely, patients and neurologists continue to look for additional options.

Revival Research Institute is conducting CIDP research studies in Texas for adults with a documented diagnosis of Chronic Inflammatory Demyelinating Polyneuropathy who remain dependent on treatment. The study is designed to evaluate the safety and efficacy of an investigational intravenous immunoglobulin therapy being studied for CIDP.

An important point about this study: participants must first have their current CIDP treatment reduced and then stopped, under close supervision from the study team, so the study can confirm that their disease is still active and still treatment dependent. Participants are seen every three weeks during this period and are moved into the treatment phase of the study as soon as any worsening is confirmed, so that further decline is avoided. This is discussed in full detail with you and your physician before you make any decision to take part.

**All study-related procedures and study treatments are provided at no cost to eligible participants. No insurance is required to participate.

*To take the next step, submit the form above, and our research staff will contact you to determine if you qualify. A brief discussion about your health and medical history may be required..

Get Started
What to Expect?

If you are an adult living with CIDP, you may qualify for CIDP Clinical Trials exploring potential treatment options. After completing the interest form above, a member of our research team will contact you for a brief pre-screening discussion to determine whether the initial eligibility requirements are met.

If you appear to qualify, an Informed Consent Form (ICF) will be reviewed and signed. This document explains the study procedures, the treatment reduction period, potential risks, possible benefits, and participant responsibilities before any decision to participate is made. You are free to ask questions at any point and free to withdraw at any time.

Once consent is provided, you will be invited to one of Revival Research Institute’s study sites for screening evaluations. These assessments may include a physical and neurological examination, review of medical history and prior CIDP treatment, vital signs, laboratory testing, disability and strength assessments, and other evaluations required by the study protocol.

Participants who meet all study requirements may be enrolled in the study. Our team will make sure you and your loved one fully understand what participation involves and what to expect throughout the study duration. You are encouraged to ask questions at any time.

Get Started
Age Icon
Age
≥18 years
Condition Icon
Condition
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Location Icon
Location
Texas

Chronic Inflammatory Demyelinating Polyneuropathy A Rare Autoimmune Nerve Disorder

Chronic Inflammatory Demyelinating Polyneuropathy Clinical Trials
CIDP is an acquired autoimmune condition affecting the peripheral nervous system. Repeated cycles of inflammation damage the myelin sheath surrounding nerve fibers, and over time the inflammation can also damage the nerve fibers themselves. The motor and sensory nerve roots and peripheral nerves are most often affected, while the nerves controlling breathing, bladder, and bowel function are usually spared. Diagnosis is made clinically, supported by nerve conduction studies and other testing, rather than by a single blood test.

CIDP May Present Through

  • Progressive weakness in the arms and legs, usually on both sides
  • Numbness, tingling, or loss of sensation in the hands and feet
  • Difficulty walking, climbing stairs, or rising from a seated position
  • Loss of grip strength and difficulty with buttons, keys, or utensils
  • Loss or reduction of deep tendon reflexes
  • Persistent fatigue

Common Features Associated with CIDP Include

  • A course that either progresses steadily or relapses and remits over time
  • Symptoms that develop gradually, typically over eight weeks or longer
  • Ongoing dependence on treatment to maintain function
  • Return or worsening of symptoms when treatment is reduced or delayed
  • Reduced mobility and increasing difficulty with everyday tasks
  • Impact on work, independence, and quality of life
The presentation and severity of CIDP vary considerably between individuals, and symptoms can change over the course of the disease.

Frequently Asked Questions

Your Guide to Chronic Inflammatory Demyelinating Polyneuropathy

Got questions about CIDP? You’re not alone. We’ve compiled answers to some of the most common questions about CIDP, including its causes, symptoms, diagnosis, treatment, and clinical trial participation. Still have questions? Contact our research team for more information. Call us at +1 (248) 721-9539, we’ll be happy to assist you.

CIDP is a rare autoimmune disorder in which the immune system attacks the myelin covering of the peripheral nerves. The damage slows or blocks nerve signals, which causes progressive weakness, sensory loss, and impaired motor function, most often in the arms and legs. Symptoms typically develop over eight weeks or longer, which distinguishes CIDP from more rapid conditions such as Guillain-Barré syndrome.
The exact cause is not fully understood. CIDP is considered an immune-mediated condition, meaning the immune system mistakenly targets healthy nerve tissue. It is not inherited and it is not contagious. In some people, symptoms first appear after an infection or another immune trigger, but in many cases no clear trigger is identified.
Diagnosis combines a clinical and neurological examination with supporting tests. These commonly include nerve conduction studies and electromyography (EMG), blood work to rule out other causes, and in some cases cerebrospinal fluid analysis, MRI, or nerve biopsy. Physicians generally apply established diagnostic criteria, such as the 2021 European Academy of Neurology / Peripheral Nerve Society (EAN/PNS) guidelines, to confirm the diagnosis.
Treatment is individualized. Commonly used approaches include immunoglobulin therapy given intravenously or subcutaneously, corticosteroids, and plasma exchange, often alongside physical or occupational therapy to maintain strength and function. Many people require ongoing maintenance treatment, because symptoms can return when treatment is reduced or stopped. Treatment decisions should always be made with a qualified healthcare provider.